journal
MENU ▼
Read by QxMD icon Read
search

Lancet

journal
https://www.readbyqxmd.com/read/30449625/radiotherapy-plus-cetuximab-or-cisplatin-in-human-papillomavirus-positive-oropharyngeal-cancer-nrg-oncology-rtog-1016-a-randomised-multicentre-non-inferiority-trial
#1
Maura L Gillison, Andy M Trotti, Jonathan Harris, Avraham Eisbruch, Paul M Harari, David J Adelstein, Erich M Sturgis, Barbara Burtness, John A Ridge, Jolie Ringash, James Galvin, Min Yao, Shlomo A Koyfman, Dukagjin M Blakaj, Mohammed A Razaq, A Dimitrios Colevas, Jonathan J Beitler, Christopher U Jones, Neal E Dunlap, Samantha A Seaward, Sharon Spencer, Thomas J Galloway, Jack Phan, James J Dignam, Quynh Thu Le
BACKGROUND: Patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma have high survival when treated with radiotherapy plus cisplatin. Whether replacement of cisplatin with cetuximab-an antibody against the epidermal growth factor receptor-can preserve high survival and reduce treatment toxicity is unknown. We investigated whether cetuximab would maintain a high proportion of patient survival and reduce acute and late toxicity. METHODS: RTOG 1016 was a randomised, multicentre, non-inferiority trial at 182 health-care centres in the USA and Canada...
November 15, 2018: Lancet
https://www.readbyqxmd.com/read/30449624/de-intensified-treatment-in-human-papillomavirus-positive-oropharyngeal-cancer
#2
Johannes Christiaan Oosthuizen, Jaime Doody
No abstract text is available yet for this article.
November 15, 2018: Lancet
https://www.readbyqxmd.com/read/30449623/radiotherapy-plus-cisplatin-or-cetuximab-in-low-risk-human-papillomavirus-positive-oropharyngeal-cancer-de-escalate-hpv-an-open-label-randomised-controlled-phase-3-trial
#3
Hisham Mehanna, Max Robinson, Andrew Hartley, Anthony Kong, Bernadette Foran, Tessa Fulton-Lieuw, Matthew Dalby, Pankaj Mistry, Mehmet Sen, Lorcan O'Toole, Hoda Al Booz, Karen Dyker, Rafael Moleron, Stephen Whitaker, Sinead Brennan, Audrey Cook, Matthew Griffin, Eleanor Aynsley, Martin Rolles, Emma De Winton, Andrew Chan, Devraj Srinivasan, Ioanna Nixon, Joanne Grumett, C René Leemans, Jan Buter, Julia Henderson, Kevin Harrington, Christopher McConkey, Alastair Gray, Janet Dunn
BACKGROUND: The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed for treatment de-escalation in this setting to reduce the toxicity of standard cisplatin treatment, but no randomised evidence exists for the efficacy of this strategy. METHODS: We did an open-label randomised controlled phase 3 trial at 32 head and neck treatment centres in Ireland, the Netherlands, and the UK, in patients aged 18 years or older with HPV-positive low-risk oropharyngeal cancer (non-smokers or lifetime smokers with a smoking history of <10 pack-years)...
November 15, 2018: Lancet
https://www.readbyqxmd.com/read/30448015/the-health-of-palestinians
#4
LETTER
Rita Giacaman
No abstract text is available yet for this article.
November 14, 2018: Lancet
https://www.readbyqxmd.com/read/30429051/stopping-medication-for-heart-failure-with-improved-ejection-fraction
#5
Jane Wilcox, Clyde W Yancy
No abstract text is available yet for this article.
November 9, 2018: Lancet
https://www.readbyqxmd.com/read/30429050/withdrawal-of-pharmacological-treatment-for-heart-failure-in-patients-with-recovered-dilated-cardiomyopathy-tred-hf-an-open-label-pilot-randomised-trial
#6
Brian P Halliday, Rebecca Wassall, Amrit S Lota, Zohya Khalique, John Gregson, Simon Newsome, Robert Jackson, Tsveta Rahneva, Rick Wage, Gillian Smith, Lucia Venneri, Upasana Tayal, Dominique Auger, William Midwinter, Nicola Whiffin, Ronak Rajani, Jason N Dungu, Antonis Pantazis, Stuart A Cook, James S Ware, A John Baksi, Dudley J Pennell, Stuart D Rosen, Martin R Cowie, John G F Cleland, Sanjay K Prasad
BACKGROUND: Patients with dilated cardiomyopathy whose symptoms and cardiac function have recovered often ask whether their medications can be stopped. The safety of withdrawing treatment in this situation is unknown. METHODS: We did an open-label, pilot, randomised trial to examine the effect of phased withdrawal of heart failure medications in patients with previous dilated cardiomyopathy who were now asymptomatic, whose left ventricular ejection fraction (LVEF) had improved from less than 40% to 50% or greater, whose left ventricular end-diastolic volume (LVEDV) had normalised, and who had an N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) concentration less than 250 ng/L...
November 9, 2018: Lancet
https://www.readbyqxmd.com/read/30424892/sglt2-inhibitors-for-primary-and-secondary-prevention-of-cardiovascular-and-renal-outcomes-in-type-2-diabetes-a-systematic-review-and-meta-analysis-of-cardiovascular-outcome-trials
#7
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc S Sabatine
BACKGROUND: The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on specific cardiovascular and renal outcomes and whether heterogeneity is based on key baseline characteristics remains undefined. METHODS: We did a systematic review and meta-analysis of randomised, placebo-controlled, cardiovascular outcome trials of SGLT2i in patients with type 2 diabetes. We searched PubMed and Embase for trials published up to Sept 24, 2018. Data search and extraction were completed with a standardised data form and any discrepancies were resolved by consensus...
November 9, 2018: Lancet
https://www.readbyqxmd.com/read/30424891/pump-pipes-and-filter-do-sglt2-inhibitors-cover-it-all
#8
Subodh Verma, Peter Jüni, C David Mazer
No abstract text is available yet for this article.
November 9, 2018: Lancet
https://www.readbyqxmd.com/read/30420125/department-of-error
#9
(no author information available yet)
No abstract text is available yet for this article.
November 9, 2018: Lancet
https://www.readbyqxmd.com/read/30420124/after-astana-building-the-economic-case-for-increased-investment-in-primary-health-care
#10
Hans Kluge, Ed Kelley, Soumya Swaminathan, Naoko Yamamoto, Senait Fisseha, Pavlos N Theodorakis, Søren Kristensen, Michael Anderson, Elias Mossialos
No abstract text is available yet for this article.
November 9, 2018: Lancet
https://www.readbyqxmd.com/read/30420123/dolutegravir-plus-lamivudine-versus-dolutegravir-plus-tenofovir-disoproxil-fumarate-and-emtricitabine-in-antiretroviral-naive-adults-with-hiv-1-infection-gemini-1-and-gemini-2-week-48-results-from-two-multicentre-double-blind-randomised-non-inferiority-phase
#11
Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, Andrea Antinori, Roberto Ortiz, Amanda E Clarke, Chien-Ching Hung, Jürgen K Rockstroh, Pierre-Marie Girard, Jörg Sievers, Choy Man, Alexander Currie, Mark Underwood, Allan R Tenorio, Keith Pappa, Brian Wynne, Anna Fettiplace, Martin Gartland, Michael Aboud, Kimberly Smith
BACKGROUND: Effective two-drug regimens could decrease long-term drug exposure and toxicity with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy and safety of a two-drug regimen compared with a three-drug region for the treatment of HIV-1 infection in ART-naive adults METHODS: We conducted two identically designed, multicentre, double-blind, randomised, non-inferiority, phase 3 trials: GEMINI-1 and GEMINI-2. Both studies were done at 192 centres in 21 countries...
November 9, 2018: Lancet
https://www.readbyqxmd.com/read/30420122/a-two-drug-regimen-for-antiretroviral-therapy
#12
Arne Kroidl, Joseph Eberle
No abstract text is available yet for this article.
November 9, 2018: Lancet
https://www.readbyqxmd.com/read/30415887/who-tracking-mechanism-for-ihr-additional-health-measures
#13
Adam Kamradt-Scott, Carmen Dolea, Corinne Poncé, Guénaël Rodier, Margaret Lamunu, Patrick Drury, Sophie Ioos
No abstract text is available yet for this article.
November 8, 2018: Lancet
https://www.readbyqxmd.com/read/30413281/safety-of-patient-facing-digital-symptom-checkers
#14
LETTER
Hamish Fraser, Enrico Coiera, David Wong
No abstract text is available yet for this article.
November 6, 2018: Lancet
https://www.readbyqxmd.com/read/30409444/licensed-chikungunya-virus-vaccine-a-possibility
#15
Ann M Powers
No abstract text is available yet for this article.
November 5, 2018: Lancet
https://www.readbyqxmd.com/read/30409443/immunogenicity-safety-and-tolerability-of-the-measles-vectored-chikungunya-virus-vaccine-mv-chik-a-double-blind-randomised-placebo-controlled-and-active-controlled-phase-2-trial
#16
Emil C Reisinger, Roland Tschismarov, Eckhard Beubler, Ursula Wiedermann, Christa Firbas, Micha Loebermann, Andrea Pfeiffer, Matthias Muellner, Erich Tauber, Katrin Ramsauer
BACKGROUND: Chikungunya fever is an emerging viral disease and substantial threat to public health. We aimed to assess the safety, tolerability, and immunogenicity of a live-attenuated, measles-vectored chikungunya vaccine (MV-CHIK). METHODS: In this double-blind, randomised, placebo-controlled and active-controlled phase 2 trial, we enrolled healthy volunteers aged 18-55 years at four study sites in Austria and Germany. Participants were randomly assigned to receive intramuscular injections with MV-CHIK (5 × 104 or 5 × 105 50% tissue culture infectious dose), control vaccine, or measles prime and MV-CHIK, in two different administration regimens...
November 5, 2018: Lancet
https://www.readbyqxmd.com/read/30396513/framing-an-agenda-for-children-thriving-in-the-sdg-era-a-lancet-commission-on-child-health-and-wellbeing
#17
Awa Coll-Seck, Helen Clark, Rajiv Bahl, Stefan Peterson, Anthony Costello, Tamara Lucas
No abstract text is available yet for this article.
November 2, 2018: Lancet
https://www.readbyqxmd.com/read/30396512/depression
#18
REVIEW
Gin S Malhi, J John Mann
Major depression is a common illness that severely limits psychosocial functioning and diminishes quality of life. In 2008, WHO ranked major depression as the third cause of burden of disease worldwide and projected that the disease will rank first by 2030.1 In practice, its detection, diagnosis, and management often pose challenges for clinicians because of its various presentations, unpredictable course and prognosis, and variable response to treatment.
November 2, 2018: Lancet
https://www.readbyqxmd.com/read/30392902/is-the-global-tuberculosis-control-strategy-too-big-to-fail
#19
LETTER
Reuben Granich
No abstract text is available yet for this article.
November 1, 2018: Lancet
https://www.readbyqxmd.com/read/30360970/efficacy-and-safety-of-filgotinib-a-selective-janus-kinase-1-inhibitor-in-patients-with-active-ankylosing-spondylitis-tortuga-results-from-a-randomised-placebo-controlled-phase-2-trial
#20
Désirée van der Heijde, Xenofon Baraliakos, Lianne S Gensler, Walter P Maksymowych, Vira Tseluyko, Oleg Nadashkevich, Walid Abi-Saab, Chantal Tasset, Luc Meuleners, Robin Besuyen, Thijs Hendrikx, Neelufar Mozaffarian, Ke Liu, Joy M Greer, Atul Deodhar, Robert Landewé
BACKGROUND: At present, biological disease-modifying anti-rheumatic drugs (DMARDs) are the only treatment recommended for patients with ankylosing spondylitis who have not responded to first-line treatment with non-steroidal anti-inflammatory drugs (NSAIDs). The TORTUGA trial investigated the efficacy and safety of filgotinib, an oral selective Janus kinase 1 (JAK1) inhibitor, for the treatment of patients with active ankylosing spondylitis. METHODS: In this completed, randomised, double-blind, placebo-controlled, phase 2 trial, we enrolled adult patients from 30 sites in seven countries (Belgium, Bulgaria, Czech Republic, Estonia, Poland, Spain, and Ukraine)...
October 22, 2018: Lancet
journal
journal
20186
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"